A pilot study of the effect of genistein in combination with high-dose interleukin-2 on cell expansion and gene expression in patients with metastatic melanoma or renal cell carcinoma
Phase of Trial: Phase 0
Latest Information Update: 13 Apr 2015
At a glance
- Drugs Aldesleukin (Primary) ; Genistein
- Indications Malignant melanoma; Renal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 09 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 May 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.